This study aimed to systematically evaluate the effectiveness of Baduanjin in the treatment of lumbar disc herniation (LDH). We searched PubMed, the Cochrane Library, EMBASE, Web of Science (WOS), CNKI, and Wanfang Databases from their inception until August 1, 2021, to collect the randomized controlled trials (RCTs) of Baduanjin in the treatment of LDH. After literature screening, data extraction, and quality evaluation by two independent researchers, the RevMan 5.4 software was used for meta-analysis. A total of 13 studies, involving 853 patients were finally included. The results showed that compared with the control group, the Baduanjin group showed remarkably improved treatment efficiency (RR=1.14, 95% CI (1.05, 1.23), P=0.001), JOA score (MD=2.62, 95% CI (0.56, 4.68), P=0.01), and VAS score (MD=−0.87, 95% CI (−1.14, −0.60), P<0.00001). The Baduanjin group exhibited higher VAS scores than the control group in different intervention times (within 1 month, 1–2 months, and more than two months) (P<0.05). Moreover, the JOA score of the Baduanjin was better than that of the control group in the presence of intervention for more than two months (MD=4.17, 95% CI (1.05, 7.30), P=0.009). In the comparison of exercise therapy, Baduanjin has more advantages than traditional rehabilitation training, as manifested by the improved VAS score (MD=−0.60, 95% CI (−0.83, −0.36), P<0.00001) and JOA score (MD=2.63, 95% CI (1.63, 3.09), P<0.00001). Conclusion: Baduanjin can significantly improve the rehabilitation evaluation scores of LDH patients and the treatment efficiency, and its curative effect was more obvious in a long time.